Promising New PD Fluid

In a Phase 2 study, PD-protec® from Zytoprotec in Vienna, Austria, reduced the risk of peritonitis and of membrane failure. The new fluid was well-tolerated, with no adverse events. Once on the market, this fluid could improve PD outcomes and allow more people to stay longer on the therapy.

Read the full article » | Posted 07/14/2017

Related Articles